Analytical Data
-
Gene name
AKR1B1
- Application
-
Alternative Names
AKR1B1；ALDR1；ALR2；Aldo-keto reductase family 1 member B1
-
Species
Human
-
Source
E. coli
-
Tag
N-6His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P15121
-
Expression Region
1-316aa
-
Molecular Weight
39 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
AKR1B1, also known as aldose reductase, is a key enzyme involved in glucose metabolism and the polyol pathway, which converts glucose into sorbitol. This enzyme has gained significant research interest due to its potential role in various health conditions, particularly diabetic complications, as it is implicated in the accumulation of sorbitol in cells, leading to osmotic and oxidative stress. Furthermore, AKR1B1 is associated with several other pathological conditions, including cataract formation, neuropathy, and cardiovascular diseases. Given its importance in disease mechanisms, researchers are investigating AKR1B1 as a therapeutic target for the development of new drugs aimed at mitigating diabetic complications. The expression and characterization of recombinant AKR1B1 protein are crucial for understanding its biochemical properties and developing inhibitors that could selectively modulate its activity. By producing AKR1B1 in a recombinant system, scientists can obtain large quantities of the enzyme for functional studies, structural analyses, and high-throughput screening of potential inhibitors. This research ultimately aims to contribute to improved treatment strategies for diabetes and related disorders, highlighting the importance of AKR1B1 in biomedical research and drug development.
